-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5346 tablets, agreeing to carry out phase III clinical trials of this product. Application indications: Reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease with elevated lipoprotein (a) or increased risk of first-time cardiovascular events.

Zhitongcaijing·11/09/2026 09:09:11
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5346 tablets, agreeing to carry out phase III clinical trials of this product. Application indications: Reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease with elevated lipoprotein (a) or increased risk of first-time cardiovascular events.